by Michael Fernando and Josh Hurwitz
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.<hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Language
🇺🇲
Publishing Since
7/31/2022
Email Addresses
1 available
Phone Numbers
0 available
April 5, 2025
<p>Today, we discuss the role of triplet therapy (ie, chemotherapy and androgen receptor signalling inhibitor and ADT) in high-volume metastatic hormone-sensitive prostate cancer and whether darolutamide is equivalent to the other androgen receptor signalling inhibitors in the castrate-sensitive space. Two good trials, and as always, some interesting discussion points.</p><br><p><strong>Studies discussed in the episode:</strong></p><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2119115" rel="noopener noreferrer" target="_blank">ARASENS</a></p><p><a href="https://ascopubs.org/doi/10.1200/JCO-24-01798" rel="noopener noreferrer" target="_blank">ARANOTE</a></p><br><p>For more episodes, resources and blog posts, visit <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com" rel="noopener noreferrer" target="_blank">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!" rel="noopener noreferrer" target="_blank">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href="mailto:[email protected]" rel="noopener noreferrer" target="_blank">[email protected]</a></p><br><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><br><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><br><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p><br><p><br></p><br><p><br></p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
March 29, 2025
<p>The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.</p><br><p><strong>Studies discussed in the episode:</strong></p><p><a href="https://pubmed.ncbi.nlm.nih.gov/31329516/" rel="noopener noreferrer" target="_blank">ARCHES</a></p><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1903835" rel="noopener noreferrer" target="_blank">ENZAMET</a></p><br><p>For more episodes, resources and blog posts, visit <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com" rel="noopener noreferrer" target="_blank">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!" rel="noopener noreferrer" target="_blank">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href="mailto:[email protected]" rel="noopener noreferrer" target="_blank">[email protected]</a></p><br><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><br><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><br><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p><br><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
March 22, 2025
<p>Our final breast cancer episode is here! Today, we are talking about the role of Gene Expression Assays in early hormone receptor-positive breast cancer management. The specific questions we asked included when we can de-escalate and for which cohort of patients these assays can be used. There's lots more to this episode, but we explore the role of Oncotype Dx!</p><br><p><strong>Studies discussed in the episode:</strong></p><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa1804710" rel="noopener noreferrer" target="_blank">TAILORx</a></p><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2108873" rel="noopener noreferrer" target="_blank">RxPonder</a></p><br><p>For more episodes, resources and blog posts, visit <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com" rel="noopener noreferrer" target="_blank">www.inquisitiveonc.com</a></p><p>Please find us on Twitter <a href="https://open.acast.com/networks/62d20dbcffef490011c8df4d/shows/62d20dbcffef490011c8df4b/episodes/@InquisitiveOnc!" rel="noopener noreferrer" target="_blank">@InquisitiveOnc!</a></p><p>If you want us to look at a specific trial or subject, email us at <a href="mailto:[email protected]" rel="noopener noreferrer" target="_blank">[email protected]</a></p><br><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><br><p>Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.</p><br><p>Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content.</p><p><br></p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>
Sam and Karine
Vinay Prasad, MD MPH
The Oncology Network
NEJM Group
NEJM Group
The Wall Street Journal
Thoracic Oncology Group Of Australasia (TOGA)
Vox Media Podcast Network
Mamamia Podcasts
The Curbsiders Internal Medicine Podcast
Peter Attia, MD
Hugh van Cuylenburg, Ryan Shelton & Josh van Cuylenburg
Freakonomics Radio + Stitcher
Vox
STAT
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at [email protected] for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.